Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats
Research article published in Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Abstract
OBJECTIVE: To promote the nasal absorption of recombinant hirudin-2, the preparation and physicochemical properties of recombinant hirudin-2 liposomes, as well as its pharmacokinetic characteristics and bioavailability in rats after nasal administration were investigated. METHOD: Recombinant hirudin-2 liposomes were prepared by reversal phase evaporation; the test of physicochemical properties including encapsulation efficiency, particle size and stability of liposome suspensions were determined by HPLC; Recombinant hirudin-2 concentration in plasma was determined by chromogenic substrate method and the relative bioavailability and pharmacokinetic parameters were also calculated using software program 3p87. RESULT: The encapsulation efficiency of recombinant hirudin-2 liposome reached greater than 76.95%, with an average particle size of about 168.3 nm, size distribution ranging from 24 to 286 nm, relative peak width of +/- 0.47, and a good stability. CONCLUSION: Compared with recombinant hirudin-2 solution, liposome preparation enhanced the nasal absorption of recombinant hirudin-2.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
To promote the nasal absorption of recombinant hirudin-2, the preparation and physicochemical properties of recombinant hirudin-2 liposomes, as well as its pharmacokinetic characteristics and bioavailability in rats after nasal administration were investigated.
Por qué esto importa para la hirudoterapia
Este estudio examinó la preparación, las propiedades fisicoquímicas y la farmacocinética de liposomas de hirudina-2 recombinante tras la administración nasal en ratas. Preparados mediante evaporación en fase inversa, los liposomas alcanzaron eficiencias de encapsulación superiores al 76,95 %, un tamaño de partícula promedio de aproximadamente 168,3 nm con buena estabilidad, y una mayor absorción nasal en comparación con la solución de hirudina-2 recombinante. Esto puede ser relevante para el ámbito de la ASH, ya que explora una vía de administración alternativa para la hirudina, un péptido ampliamente reconocido como anticoagulante derivado de la sanguijuela y central en la hirudoterapia, aunque el resumen en sí no menciona el origen en la sanguijuela. Se trata de un estudio farmacocinético preclínico en animales sin datos clínicos; no se involucran directamente sanguijuelas ni hirudoterapia.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026